Sanofi set to offer insulin products at $35 per month for all US patients
PositiveFinancial Markets

Sanofi has announced a groundbreaking initiative to offer its insulin products at a flat rate of $35 per month for all patients in the United States. This move is significant as it addresses the rising costs of diabetes management, making essential medication more accessible to millions who struggle with affordability. By implementing this pricing strategy, Sanofi aims to alleviate financial burdens and improve health outcomes for those living with diabetes.
— Curated by the World Pulse Now AI Editorial System